HCCS Serves as Potential Prognostic Biomarker and Therapeutic Target in Human Breast Cancer.

ABSTRACT:

Background

Breast cancer is a leading cause of cancer-related morbidity and mortality in women worldwide. Among its subtypes, triple-negative breast cancer (TNBC) poses the greatest therapeutic challenge due to its aggressive nature and lack of targeted treatments. Holocytochrome c synthase (HCCS), a mitochondrial enzyme essential for cytochrome c maturation, may play a pivotal role in cancer pathogenesis.

Objective

This study aimed to investigate the expression profile, epigenetic regulation, immune interactions, prognostic significance, and molecular networks of HCCS across cancers, with a particular focus on breast cancer and its subtypes.

Methods

Publicly available datasets and bioinformatics tools were employed to analyze HCCS expression, methylation, survival ou

SUBMITTER: Bellah SF 

PROVIDER: S-EPMC12752879 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature